Want to see HCWB full AI Analyst Report?
HCWB Stock Chart & Stats
$3.17
-$0.38(-13.19%)
At close: 4:00 PM EDT
$3.17
-$0.38(-13.19%)
Day’s Range― - ―
52-Week Range$1.50 - $36.64
Previous CloseN/A
Volume56.72K
Average Volume (3M)159.11K
Market Cap
$5.40M
Enterprise Value$12.45
Total Cash (Recent Filing)$741.32K
Total Debt (Recent Filing)$6.56M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Nov 12, 2026EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-54.17
Shares Outstanding1,836,324
10 Day Avg. Volume210,024
30 Day Avg. Volume159,109
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.74
Price to Sales (P/S)37.52
P/FCF Ratio-0.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$30.00Price Target Upside846.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.88
Revenue Forecast (FY)$900.00K
Bulls Say, Bears Say
Bulls Say
Promising HCW9302 Phase 1 DataEarly human efficacy and tolerability signals support continued development of HCW9302 and its Treg-focused mechanism. If confirmed in larger cohorts, the program could broaden into autoimmune and inflammatory indications.
Improved Balance SheetLower debt and positive equity provide a stronger financial base than prior periods, reducing immediate leverage pressure. This improvement gives management more flexibility while clinical programs progress, despite historical capital structure volatility.
Resolution Of Liabilities And LiensSettling disputed obligations removes legal uncertainty and encumbrances from key infrastructure while improving clarity around liabilities. It may also preserve relationships with operational partners needed for future clinical manufacturing.
Bears Say
Persistent UnprofitabilityThe company is still far from covering operating costs through its business activities. Persistent losses limit internal funding capacity and make future progress dependent on successful clinical execution, partnerships, or additional external capital.
Sustained Cash BurnNegative operating and free cash flow show that research activities are not self-funding and that accounting improvements have not translated into cash generation. Continued development will therefore consume liquidity and increase financing requirements.
Financing And Listing DependenceReliance on small equity financings exposes shareholders to dilution and may constrain the pace of clinical investment. Continued Nasdaq monitoring adds structural financing and market-access risk if another listing deficiency occurs.
HCW Biologics News
HCWB FAQ
What was HCW Biologics’s price range in the past 12 months?
HCW Biologics lowest stock price was $1.50 and its highest was $36.64 in the past 12 months.
What is HCW Biologics’s market cap?
HCW Biologics’s market cap is $5.40M.
When is HCW Biologics’s upcoming earnings report date?
HCW Biologics’s upcoming earnings report date is Nov 12, 2026 which is in 67 days.
How were HCW Biologics’s earnings last quarter?
HCW Biologics released its earnings results on Aug 14, 2026. The company reported -$11.58 earnings per share for the quarter, missing the consensus estimate of -$1.98 by -$9.6.
Is HCW Biologics overvalued?
According to Wall Street analysts HCW Biologics’s price is currently Undervalued.
Does HCW Biologics pay dividends?
HCW Biologics does not currently pay dividends.
What is HCW Biologics’s EPS estimate?
HCW Biologics’s EPS estimate is -1.08.
How many shares outstanding does HCW Biologics have?
HCW Biologics has 1,836,324 shares outstanding.
What happened to HCW Biologics’s price movement after its last earnings report?
HCW Biologics reported an EPS of -$11.58 in its last earnings report, missing expectations of -$1.98. Following the earnings report the stock price went down -8.376%.
Which hedge fund is a major shareholder of HCW Biologics?
Currently, no hedge funds are holding shares in HCWB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
HCW Biologics
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
HCWB Stock 12 Month Forecast
Average Price Target
$30.00
▲(846.37% Upside)
Technical Analysis
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Xenetic Biosciences
―
Addex Therapeutics
―
Calidi Biotherapeutics
―
Ownership Overview
12.71% Insiders
1.35% Mutual Funds
0.18% Other Institutional Investors
85.65% Public Companies and
Individual Investors